Illumina’s sequencing machines are estimated to control 90% of the market in the US and compile 80% of genomic information that exists in the world in a given year. The company is sometimes described as the ‘Google of the genomics business’, not just because it commands its market, but also due to its products’ ability to ’search’ our complete genetic makeup. Illumina enables its customers to read and understand genetic variations. Its products allow for the sequencing of genomes at an unprecedented scale. In fact, it sequenced the novel coronavirus in just two days, with Moderna taking an additional two days to translate that sequencing data into a mRNA molecule, which is the basis of its vaccine.